Ralph Zitnik
Overview
Explore the profile of Ralph Zitnik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
1324
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Szefler S, Corren J, Silverberg J, Okragly A, Sun Z, Natalie C, et al.
Immunotherapy
. 2025 Jan;
16(20-22):1211-1216.
PMID: 39781908
Aim: Lebrikizumab is an interleukin (IL)-13 inhibitor that specifically blocks IL-13 signaling. Here, we report the effects of lebrikizumab on asthma serum biomarkers in 2 phase 3 clinical studies. Methods:...
2.
Corren J, Szefler S, Sher E, Korenblat P, Soong W, Hanania N, et al.
J Allergy Clin Immunol Pract
. 2024 Feb;
12(5):1215-1224.e3.
PMID: 38360213
Background: LAVOLTA (L)I, LII, and ACOUSTICS were randomized, placebo-controlled, Phase 3 trials of lebrikizumab, a monoclonal antibody targeting IL-13 in patients with uncontrolled asthma. Failure to demonstrate efficacy may have...
3.
DHaens G, Eberhardson M, Cabrijan Z, Danese S, van den Berg R, Lowenberg M, et al.
J Crohns Colitis
. 2023 Sep;
17(12):1897-1909.
PMID: 37738465
Background And Aims: Crohn's disease [CD] is a debilitating, inflammatory condition affecting the gastrointestinal tract. There is no cure and sustained clinical and endoscopic remission is achieved by fewer than...
4.
Doko I, Grazio S, Grubisic F, Zitnik R
Reumatizam
. 2018 Apr;
63(2):1-8.
PMID: 29624032
Objective: Electrical stimulation of the vagus has proven effective in various inflammatory conditions in animal
models. The aim of this study is to show the effect of vagal nerve neurostimulation...
5.
Koopman F, Chavan S, Miljko S, Grazio S, Sokolovic S, Schuurman P, et al.
Proc Natl Acad Sci U S A
. 2016 Jul;
113(29):8284-9.
PMID: 27382171
Rheumatoid arthritis (RA) is a heterogeneous, prevalent, chronic autoimmune disease characterized by painful swollen joints and significant disabilities. Symptomatic relief can be achieved in up to 50% of patients using...
6.
Levine Y, Koopman F, Faltys M, Caravaca A, Bendele A, Zitnik R, et al.
PLoS One
. 2014 Aug;
9(8):e104530.
PMID: 25110981
Introduction: The inflammatory reflex is a physiological mechanism through which the nervous system maintains immunologic homeostasis by modulating innate and adaptive immunity. We postulated that the reflex might be harnessed...
7.
Hutmacher M, Nestorov I, Ludden T, Zitnik R, Banfield C
J Clin Pharmacol
. 2007 Jan;
47(2):238-48.
PMID: 17244775
Modeling exposure-response relationships adds significant value to comprehending and interpreting both efficacy and safety data. An exposure-response model was developed using generalized nonlinear mixed-effects methodologies to correlate etanercept exposure with...
8.
Nestorov I, Zitnik R, DeVries T, Nakanishi A, Wang A, Banfield C
Br J Clin Pharmacol
. 2006 Sep;
62(4):435-45.
PMID: 16995864
Aims: To present the results of the pharmacokinetic analysis of the concentration-time profiles of etanercept, a soluble receptor tumour necrosis factor (TNF) antagonist, in more than 1300 subjects with psoriasis....
9.
Gottlieb A, Leonardi C, Goffe B, Ortonne J, van der Kerkhof P, Zitnik R, et al.
J Am Acad Dermatol
. 2006 Feb;
54(3 Suppl 2):S92-100.
PMID: 16488335
Background: Etanercept, a tumor necrosis factor antagonist, is an approved treatment in the United States and Europe for plaque psoriasis. Objective: To further examine the safety profile of etanercept in...
10.
Krueger G, Elewski B, Papp K, Wang A, Zitnik R, Jahreis A
J Am Acad Dermatol
. 2006 Feb;
54(3 Suppl 2):S112-9.
PMID: 16488321
Background: Etanercept provides rapid, significant improvement in psoriatic symptoms and disease. Objective: The effectiveness of continued etanercept treatment beyond 24 weeks in patients who initially did not achieve at least...